Neuroblastoma patients response to immunotherapy predicted by genetic profiling
2016
Memorial Sloan Kettering Cancer Center, New York, USA
Half of the patients with neuroblastoma (NB) have a high-risk disease at diagnosis with poor long-term survival. Monoclonal antibody (mAb) therapies directed at disialoganglioside GD2 mediate the action of Natural Killer cells (NK cells) and have been a major advancement in the treatment of NB. NK cells activity rely on the presence and interaction of certain cell surface receptors and ligands. In the present study, the researchers aimed at understanding if a specific combination of one cell surface receptor and ligand could help to predict the outcome of patients treated with monoclonal antibodies. A cohort of patients was genetically profiled for the presence of receptor and ligand and was correlated with patients outcomes following treatment. The results showed the best outcome when the patient has weak interacting receptors and ligands, hence potentially helping the prediction of prognosis.
KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to anti-GD2 monoclonal antibody in patients with neuroblastoma
Katharine C. Hsu
Added on: 09-17-2021
[1] https://ascopubs.org/doi/abs/10.1200/JCO.2015.64.9558[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
